Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer
The aim: to compare disease-free survival time (DFS) in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant hyperthermic intravesical chemotherapy and standard BCG therapy. Materials and methods: patients were divided into 2 groups. Group 1 (control) included patients who...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
PC Technology Center
2021-04-01
|
Series: | ScienceRise: Medical Science |
Subjects: | |
Online Access: | http://journals.uran.ua/sr_med/article/view/228185 |
id |
doaj-12d20ecd274747408692cbac85ca26c1 |
---|---|
record_format |
Article |
spelling |
doaj-12d20ecd274747408692cbac85ca26c12021-04-20T13:15:21ZengPC Technology CenterScienceRise: Medical Science2519-478X2519-47982021-04-012(41)222710.15587/2519-4798.2021.228185265730Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancerRoman Chystiakov0https://orcid.org/0000-0002-7049-7628Odessa National Medical UniversityThe aim: to compare disease-free survival time (DFS) in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant hyperthermic intravesical chemotherapy and standard BCG therapy. Materials and methods: patients were divided into 2 groups. Group 1 (control) included patients who received adjuvant therapy after TURB with BCG vaccine (BCG therapy group; n=50), group 2 (study group) included patients (HIVEC® therapy group; n=46 ), who received adjuvant intravesical chemotherapy using a Combat BRS HIVEC® device for local hyperthermia. Results: median follow-up was 23 months (range 4 - 36). Tumor recurrence was reported in 19 patients receiving intravesical BCG therapy and in 8 patients receiving intravesical hyperthermic chemotherapy. The incidence of DFS in patients receiving chemohyperthermy was statistically higher than in patients receiving BCG therapy (log-rank test result: p=0.029). Conclusions: The method of hyperthermic intravesical chemotherapy significantly increased the 2-year disease-free survival rate - 82.6 % versus 62 % BCG therapy group (p=0.025). Its use in the future will allow increasing the frequency of organ-preserving treatment of patients with primary and recurrent muscular-non-invasive bladder tumorshttp://journals.uran.ua/sr_med/article/view/228185non-muscle invasive bladder cancerhyperthermic intravesical chemotherapybcg therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roman Chystiakov |
spellingShingle |
Roman Chystiakov Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer ScienceRise: Medical Science non-muscle invasive bladder cancer hyperthermic intravesical chemotherapy bcg therapy |
author_facet |
Roman Chystiakov |
author_sort |
Roman Chystiakov |
title |
Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer |
title_short |
Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer |
title_full |
Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer |
title_fullStr |
Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer |
title_full_unstemmed |
Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer |
title_sort |
prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer |
publisher |
PC Technology Center |
series |
ScienceRise: Medical Science |
issn |
2519-478X 2519-4798 |
publishDate |
2021-04-01 |
description |
The aim: to compare disease-free survival time (DFS) in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant hyperthermic intravesical chemotherapy and standard BCG therapy.
Materials and methods: patients were divided into 2 groups. Group 1 (control) included patients who received adjuvant therapy after TURB with BCG vaccine (BCG therapy group; n=50), group 2 (study group) included patients (HIVEC® therapy group; n=46 ), who received adjuvant intravesical chemotherapy using a Combat BRS HIVEC® device for local hyperthermia.
Results: median follow-up was 23 months (range 4 - 36). Tumor recurrence was reported in 19 patients receiving intravesical BCG therapy and in 8 patients receiving intravesical hyperthermic chemotherapy. The incidence of DFS in patients receiving chemohyperthermy was statistically higher than in patients receiving BCG therapy (log-rank test result: p=0.029).
Conclusions: The method of hyperthermic intravesical chemotherapy significantly increased the 2-year disease-free survival rate - 82.6 % versus 62 % BCG therapy group (p=0.025). Its use in the future will allow increasing the frequency of organ-preserving treatment of patients with primary and recurrent muscular-non-invasive bladder tumors |
topic |
non-muscle invasive bladder cancer hyperthermic intravesical chemotherapy bcg therapy |
url |
http://journals.uran.ua/sr_med/article/view/228185 |
work_keys_str_mv |
AT romanchystiakov prospectsfortheuseofthemethodofintravesicalhyperthermicchemotherapyinthetreatmentofpatientswithnonmuscleinvasivebladdercancer |
_version_ |
1721517798282231808 |